Nervous System Active Pharmaceutical Ingredients Market Report 2026

Nervous System Active Pharmaceutical Ingredients Market Overview

• Nervous System Ingredients-global-market-report" target="_blank">Active Pharmaceutical Ingredients market size has reached to $254.73 billion in 2025 • Expected to grow to $334.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: The Rising Prevalence Of Neurological Disorders Driving The Growth Of The Market Due To Aging Population And Increasing Disease Burden • Market Trend: Innovations In Nervous System Active Pharmaceutical Ingredient (API) Development Support Advanced Neurological And Pain Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nervous System Active Pharmaceutical Ingredients Market?

Nervous system active pharmaceutical ingredients are pharmacologically active substances that are formulated to act on the central and peripheral nervous system to diagnose, treat, prevent, or manage neurological and psychiatric disorders. Nervous system active pharmaceutical ingredients are designed to be incorporated into finished dosage forms such as tablets, capsules, injectables, and liquid medicines used in the treatment of nervous system-related conditions. The main products of nervous system active pharmaceutical ingredients are cytokines, vaccines, fusion proteins, and therapeutic enzymes. Cytokines refer to protein-based molecules that regulate immune responses and are used in the treatment of various neurological conditions. These products are produced using different expression systems, including mammalian and microbial yeast. They are applied across multiple therapeutic areas, such as diabetes, cardiovascular diseases, oncology, and neurological disorders, and are utilized by various end-users, including pharmaceutical companies, biopharmaceutical companies, contract development and manufacturing organizations, research and development laboratories, and generic drug manufacturers.

What Is The Nervous System Active Pharmaceutical Ingredients Market Growth Forecast?

The nervous system active pharmaceutical ingredients market size is expected to see strong growth in the next few years. It will grow to $334.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growth in neurodegenerative disease burden, expansion of specialty cns therapies, rising demand for high purity apis, increase in outsourced api manufacturing, growth of biologic neuro drugs. Major trends in the forecast period include high potency neurology api development, complex cns molecule synthesis, peptide based neuro apis, controlled release neuro api formats, specialized neuro api cdmo partnerships.

What Is The Driver Of The Nervous System Active Pharmaceutical Ingredients Market?

The rising prevalence of neurological disorders is expected to propel the growth of the nervous system active pharmaceutical ingredients market going forward. Neurological disorders refer to a broad range of medical conditions that disrupt the normal functioning of the central and peripheral nervous system, often causing symptoms such as seizures, paralysis, memory loss, or coordination problems. Neurological disorders are increasing mainly due to the aging global population, as older individuals are more prone to neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease because nerve cells naturally decline and become more vulnerable to damage over time. Nervous system active pharmaceutical ingredients help in neurological disorders by modulating neural signaling and protecting nerve cells, thereby slowing disease progression and enhancing symptom control in conditions such as epilepsy, multiple sclerosis, and neurodegenerative diseases. For instance, in December 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2024, around 425,000 Australians were living with dementia. This figure is projected to rise 2.5 times, reaching over 1.1 million by 2065, including approximately 662,000 women and 390,000 men. Therefore, the rising prevalence of neurological disorders is driving the growth of the nervous system active pharmaceutical ingredients industry.

Key Players In The Global Nervous System Active Pharmaceutical Ingredients Market

Major companies operating in the nervous system active pharmaceutical ingredients market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG., Thermo Fisher Scientific Inc., GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Zydus Lifesciences Limited, Biocon Ltd., Siegfried Holding AG., Alkem Laboratories Ltd., Almac Group, Torrent Pharmaceuticals Ltd., Granules India Ltd., Wockhardt Ltd., Neuland Laboratories Ltd., Hetero Labs Ltd., MSN Laboratories Pvt. Ltd., and Piramal Pharma.

Global Nervous System Active Pharmaceutical Ingredients Market Trends and Insights

Major companies operating in the nervous system active pharmaceutical ingredients market are focusing on developing innovative solutions, such as cannabinoid-based active pharmaceutical ingredients, to enhance the efficacy, safety, and targeted delivery of treatments for neurological disorders. Cannabinoid-based active pharmaceutical ingredients (APIs) are highly purified natural or synthetic compounds that deliver therapeutic effects by targeting the body’s endocannabinoid system to manage pain, epilepsy, nausea, and various neurological conditions. For instance, in March 2024, Brains Bioceutical Corp., a Canada-based pharmaceutical company, launched solid D9 Tetrahydrocannabinol (THC), a cannabinoid-based active pharmaceutical ingredient designed to advance pharmaceutical research and drug development in neurological and pain management applications. This solid D9-THC API features a crystalline structure that improves storage stability and dosing accuracy over traditional cannabinoid extracts, facilitating its use in research and formulation development across therapeutic areas where CNS-active agents are critical. The product’s development underscores the shift toward more sophisticated API formats that can support precise, scalable pharmaceutical manufacturing.

What Are Latest Mergers And Acquisitions In The Nervous System Active Pharmaceutical Ingredients Market?

In January 2025, Johnson & Johnson, a US-based healthcare technology and pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. With this acquisition, Johnson & Johnson aimed to strengthen its neuroscience and central nervous system (CNS) therapeutic portfolio by adding new FDA-approved medicines and pipeline assets targeting psychiatric and neurodegenerative disorders, enhancing its capabilities in mental health and CNS drug development. Intra-Cellular Therapies Inc. is a US-based biopharmaceutical company that offers nervous system active pharmaceutical ingredients.

What Defines the Nervous System Active Pharmaceutical Ingredients Market?

The nervous system active pharmaceutical ingredients market consists of sales of synthetic active pharmaceutical ingredients, biologically derived active pharmaceutical ingredients, generic active pharmaceutical ingredients, and branded active pharmaceutical ingredients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nervous System Active Pharmaceutical Ingredients Market Report 2026?

The nervous system active pharmaceutical ingredients market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nervous system active pharmaceutical ingredients industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.